Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$0.56 - $1.19 $21,585 - $45,868
-38,545 Reduced 97.99%
791 $1,000
Q1 2024

May 07, 2024

BUY
$0.75 - $1.56 $396 - $825
529 Added 1.36%
39,336 $30,000
Q4 2023

Feb 01, 2024

SELL
$0.93 - $2.15 $277 - $640
-298 Reduced 0.76%
38,807 $54,000
Q3 2023

Nov 07, 2023

BUY
$2.33 - $5.07 $1,199 - $2,611
515 Added 1.33%
39,105 $93,000
Q2 2023

Aug 07, 2023

BUY
$4.67 - $6.55 $28,113 - $39,431
6,020 Added 18.48%
38,590 $185,000
Q1 2023

May 02, 2023

SELL
$4.95 - $6.09 $81,675 - $100,485
-16,500 Reduced 33.63%
32,570 $185,000
Q4 2022

Jan 30, 2023

SELL
$5.09 - $9.05 $183 - $325
-36 Reduced 0.07%
49,070 $275,000
Q3 2022

Nov 08, 2022

BUY
$3.5 - $7.2 $395 - $813
113 Added 0.23%
49,106 $315,000
Q2 2022

Aug 04, 2022

SELL
$2.7 - $7.62 $224 - $632
-83 Reduced 0.17%
48,993 $168,000
Q1 2022

May 05, 2022

SELL
$6.3 - $8.84 $4,914 - $6,895
-780 Reduced 1.56%
49,076 $349,000
Q4 2021

Feb 02, 2022

BUY
$6.02 - $11.43 $68,922 - $130,862
11,449 Added 29.81%
49,856 $415,000
Q3 2021

Nov 02, 2021

SELL
$5.46 - $22.6 $118,154 - $489,064
-21,640 Reduced 36.04%
38,407 $267,000
Q2 2021

Aug 02, 2021

BUY
$18.46 - $24.36 $161,469 - $213,076
8,747 Added 17.05%
60,047 $1.43 Million
Q1 2021

May 11, 2021

SELL
$17.66 - $28.92 $17,660 - $28,920
-1,000 Reduced 1.91%
51,300 $1.06 Million
Q4 2020

Feb 08, 2021

BUY
$23.25 - $37.73 $232,500 - $377,299
10,000 Added 23.64%
52,300 $1.28 Million
Q3 2020

Nov 05, 2020

BUY
$3.74 - $28.74 $7,480 - $57,480
2,000 Added 4.96%
42,300 $1.2 Million
Q2 2020

Aug 07, 2020

BUY
$3.04 - $6.2 $63,840 - $130,200
21,000 Added 108.81%
40,300 $192,000
Q1 2018

May 10, 2018

SELL
$7.34 - $11.16 $29,360 - $44,640
-4,000 Reduced 17.17%
19,300 $142,000
Q2 2017

Aug 11, 2017

BUY
N/A
23,300
23,300 $263,000

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $102M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.